Compare Becton Dickinson and Co (BDX) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Infosys Limited — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Infosys Limited trades at $11.05 (market cap $46.90B). The key difference: Becton Dickinson and Co and Infosys Limited are close in size by market cap, and Infosys Limited pays the higher dividend (4.74%). Which is the better fit depends on your goals.
| BDX | INFY | |
|---|---|---|
Market Cap | $41.51B | $46.90B |
Sector | Health | Technology |
52-Week High | $185.39 | $20.22 |
52-Week Low | $135.49 | $10.49 |
Enterprise Value | $57.97B | $44.12B |
Dividend Yield | 2.79% | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
INFY trades at $11.50, up 5.12% today, with a bullish technical signal and strong profitability metrics including a 16.44% net income margin and 31.57% ROE. Recent earnings beat expectations in Q4 2025 and Q1 2026, while the company is actively expanding AI collaborations in healthcare and financial services, as reported by PRNewsWire on June 24, 2026.
The stock offers a moderate valuation with a P/E of 13.81 and consensus price target of $12.14, suggesting modest upside. Risks include competitive pressures from AI automation and volatile IT spending, but institutional sentiment is mixed with 37.5% buy ratings. The dividend yield adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
